<DOC>
	<DOCNO>NCT01618019</DOCNO>
	<brief_summary>The purpose study see supplementation n-3 polyunsaturated fatty acid ( PUFA ) beneficial patient rheumatoid arthritis .</brief_summary>
	<brief_title>N-3 PUFA Rheumatoid Arthritis Korea</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients rheumatoid arthritis diagnose base American College Rheumatology guideline receiving NSAID , glucocorticoid , DMARD eligible dosage stable least 3 month prior enter study . Patients exclude pregnant , lactating , age 18 age 80 , take supplement contain n3 PUFA , white blood cell ( WBC ) ≤ 3.5 × 109/L , hemoglobin ( Hb ) ≤ 8.5 g/dL , platelet ≤ 100 × 109/L , creatinine ≥ 2.0 mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 2.5 time upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>n-3 PUFA</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>inflammation</keyword>
	<keyword>eicosanoids</keyword>
	<keyword>bone turnover marker</keyword>
</DOC>